| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 5. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | dorzolamide/timolol (Eylamdo®) |
| Formulation | 20mg/ml + 5mg/ml eye drops |
| Reference number | 3561 |
| Indication | In the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or pseudoexfoliative glaucoma when topical beta-blocker monotherapy is not sufficient |
| Company | Aspire Pharma Ltd |
| BNF chapter | Eye |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 27/07/2017 |